{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-266770","form_type":"8-K","ticker":"JAGX","cik":"0001585608","company_name":"Jaguar Health, Inc.","filed_at":"2026-06-11T13:00:07+00:00","discovered_at":"2026-06-11T13:01:00.363502+00:00","generated_at":"2026-06-11T13:01:14.319178+00:00","sec_items":["1.01","3.02","5.03","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Jaguar Health secures up to $40M equity line and $2M preferred stock financing","bullets":["ELOC agreement provides up to $40M of common stock purchases; floor price set at $1.10 per share.","Single fixed purchase capped at $1.5M; $800K commitment shares to be issued upon registration effectiveness.","Series P preferred stock financing: 240 shares at $10K stated value, 8% annual dividend, mandatory redemption with ELOC proceeds.","Stockholder approval obtained June 8, 2026 allowing issuances beyond 19.99% for both facilities.","Proceeds intended for general corporate purposes; registration statements to be filed within 30 days."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-266770","json":"https://secwatch.observer/filing/0001193125-26-266770.json","markdown":"https://secwatch.observer/filing/0001193125-26-266770.md","text":"https://secwatch.observer/filing/0001193125-26-266770.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1585608/000119312526266770/0001193125-26-266770-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1585608/000119312526266770/d570985d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T13:01:14.319178+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"13913611905191539a81538e2ad5bdbeb569a022","claim":"Jaguar Health, Inc. issued common stock to Institutional Investor.","evidence_excerpt":"In consideration for the Institutional Investor’s execution and delivery of the ELOC Agreement, the Company agreed to issue to the Institutional Investor on the effective date of the ELOC Registration Statement (as defined hereunder) $800,000 worth of the Company’s Common Stock, valued at the VWAP Purchase Price as of such effective date (the “Commitment Shares”).","evidence_source":"SEC 8-K Item 3.02/3.03","evidence_url":"https://www.sec.gov/Archives/edgar/data/1585608/000119312526266770/0001193125-26-266770-index.htm","confidence":0.9,"family_label":"Equity Issuances","details":[{"label":"Security","value":"common stock"},{"label":"Purchaser","value":"Institutional Investor"}],"fact_type":"equity_issuance"},{"claim_id":"23c0b11446d15cd69b64c4e9a4b9c05efd17a9ae","claim":"Jaguar Health, Inc.: Filed Series P Certificate of Designation with Delaware Secretary of State on June 8, 2026, effective upon filing, authorizing up to 300 shares of Series P Preferred Stock with specific dividend, voting, and liquidation preferences (effective 2026-06-08).","evidence_excerpt":"The preferences, rights, limitations and other matters relating to the Series P Preferred Stock are set forth in the Certificate of Designation, which the Company filed with the Secretary of State of the State of Delaware on June 8, 2026. The Certificate of Designation became effective with the Secretary of State of the State of Delaware upon filing. The Certificate of Designation authorizes the Company to issue up to 300 of its 4,475,074 authorized shares of preferred stock as Series P Preferred Stock.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1585608/000119312526266770/0001193125-26-266770-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2026-06-08"}],"fact_type":"governance_change"},{"claim_id":"dfa9fcd86c081a7c7790669c542a3a5c120f0847","claim":"Jaguar Health, Inc. entered into common stock purchase agreement with an accredited investor valued at up to an aggregate of $40 million (effective 2026-06-09).","evidence_excerpt":"On June 9, 2026, Jaguar Health, Inc. (the “Company”) entered into a common stock purchase agreement (the “ELOC Agreement”) with an accredited investor (the “Institutional Investor”), which provides that, upon the terms and subject to the conditions set forth therein, the Institutional Investor is committed to purchase up to an aggregate of $40 million of shares of Common Stock.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1585608/000119312526266770/0001193125-26-266770-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"an accredited investor"},{"label":"Value","value":"up to an aggregate of $40 million"},{"label":"Effective","value":"2026-06-09"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}